✨ Free AI Report
CG Oncology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research CG Oncology, Inc.
Company Research

CG Oncology, Inc.: Business Overview, Financials & Competitive Analysis

CG Oncology, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Leading oncolytic immunotherapy candidate in bladder cancer with strong clinical efficacy, multiple upcoming data catalysts in 2026, and 3+ years of cash runway positions CG Oncology as a compelling biotech investment in high-need oncology space.

What is CG Oncology, Inc.'s industry? CG Oncology, Inc. (cgoncology.com) operates in Biotechnology / Oncology. AskCyborg classifies CG Oncology, Inc. under Biotechnology / Oncology in its company registry.

CG Oncology is a late-stage clinical biopharmaceutical company that develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company is positioned as a leading contender ...

8/ 10Strong

Cyborg Score thesis

Leading oncolytic immunotherapy candidate in bladder cancer with strong clinical efficacy, multiple upcoming data catalysts in...

Read the full analyst-debate transcript →
Industry Biotechnology / Oncology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest CG Oncology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for CG Oncology, Inc.

AskCyborg analysts argue the bull and bear cases for CG Oncology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
CG Oncology, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

CG Oncology, Inc. Overview

Pro stress-test →

CG Oncology is a late-stage clinical biopharmaceutical company that develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company is positioned as a leading contender in high-risk BCG-unresponsive NMIBC with its oncolytic adenovirus, cretostimogene grenadenorepvec.

Strategic Profile

Pro stress-test →

As of February 2026, CG Oncology has approximately $903.0 million in cash to fund operations into 2029. The company announced an expedited timeline for PIVOT-006 nearly a year ahead of schedule, which is the first Phase 3 randomized trial in intermediate-risk NMIBC encompassing the broadest range of patient types per AUA/SUO Guidelines. CG Oncology maintains a "Strong Buy" rating driven by significant pipeline progress and multiple upcoming catalysts in 2026.

Competitive Landscape

Pro stress-test →

CG Oncology positions its oncolytic adenovirus cretostimogene as a leading competitor in the high-risk BCG-unresponsive NMIBC space, with efficacy and safety data rivaling Johnson & Johnson offerings. The company targets a large unmet need in bladder cancer where standard BCG therapy fails or cannot be tolerated.

Industry Context

CG Oncology, Inc. operates in Biotechnology / Oncology.

Key facts

Founded: 2010 · Headquarters: Irvine, California · Employees: 113 · Revenue: $0

What the analysts stress-tested

The top findings that survived the multi-agent debate for CG Oncology, Inc..

  • PIVOT-006 Phase 3 data expected in 1H 2026 nearly a year ahead of schedule, underscoring excitement for cretostimogene
  • BOND-003 Cohort P demonstrated high-grade event-free survival rates of 95.7%, 84.6%, and 80.4% at 3, 6, and 9-month follow-up
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Reported $903M cash position and updated financial results for 2025 with multiple upcoming catalysts
  • January 2026Announced accelerated PIVOT-006 Phase 3 timeline for intermediate-risk NMIBC data delivery
  • +2 moreTrack every material event for CG Oncology, Inc. as it happens. Explore monitoring →
Get alerted when CG Oncology, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ValrubicinFirst-line intravesical therapy for BCG-unresponsive high-risk NMIBC→Adstilidase Alfa (Adstiladrin)Oncolytic immunotherapy for high-risk BCG-unresponsive NMIBC→Checkpoint inhibitor combinationsPembrolizumab and nivolumab-based combinations in development for NMIBC→

Compare CG Oncology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

CG Oncology, Inc. operates in Biotechnology / Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology / Oncology research →
NEW · MCP server

Ask your AI assistant about CG Oncology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare CG Oncology, Inc. and its top competitor on Cyborg Score”
“What did CG Oncology, Inc. do this quarter?”
“Is CG Oncology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does CG Oncology, Inc. do?+
CG Oncology is a late-stage clinical biopharmaceutical company that develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company is positioned as a leading contender ...
What is CG Oncology, Inc.'s Cyborg Score?+
CG Oncology, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are CG Oncology, Inc.'s main competitors?+
Named competitors include Valrubicin, Adstilidase Alfa (Adstiladrin), Checkpoint inhibitor combinations. The full competitive landscape is in the AskCyborg report.
How can I get the full CG Oncology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the CG Oncology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track CG Oncology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend Biotech8NovonesisTop companies in Biotechnology by Cyborg Score